Table 3. SARS-CoV-2 seroprevalence in hospitalized patients with COVID-19, mildly symptomatic individuals, and healthy blood donors.

Cohort	ELISA N	ELISA tri-S	S-Flow	LIPS S1 + N	Antibody prevalence
Pre-pandemic individuals (specificity)	23/491 (95%)	5/100 (95%)	0/134 (100%)	3/280 (99%)
Hospitalized patients (seroprevalence)	33/51 (65%)	35/51 (69%)	21/29 (72%)	35/51 (69%)	69% (65–72%)
Mildly symptomatic individuals	56/209 (27%)	75/209 (36%)	73/209 (35%)	68/209 (32%)	32% (27–36%)
Healthy blood donors	0/200	2/16	6/200	0/200	3%